Probabilities of remission and overall survival. (A) Kaplan-Meier estimates of remission duration for patients in cohort 1 (n = 47) treated according to the alternating schedule and patients in cohort 2 (n = 45) receiving imatinib simultaneously with induction 2 chemotherapy (relative risk in the alternating treatment schedule, 1.086; 95% confidence interval, 0.5094 to 2.317; P = .83 by the log-rank test) and (B) of overall survival by treatment schedule (relative risk in the alternating treatment schedule, 1.009; 95% confidence interval, 0.5773 to 1.766; P = .97 by the log-rank test).